Pathophysiology of Acute Graft-Versus-Host Disease (GVHD)
JAK-STAT signaling pathways play a role in regulating the development, proliferation, and activation of several immune cell types important for the pathogenesis of GVHD.1-5
In a mouse model of acute GVHD, oral administration of Jakafi was associated with1:
JAK, Janus-associated kinase; STAT, signal transducer and activator of transcription.
Get information about IncyteCARES and patient support.
References
Indications and Usage
Jakafi is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
Jakafi is indicated for treatment of intermediate or high‐risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
Jakafi is indicated for treatment of steroid‐refractory acute graft‐versus‐host disease (GVHD) in adult and pediatric patients 12 years and older.
Important Safety Information
Please see Full Prescribing Information for Jakafi.
You are now leaving the Jakafi.com website.
You are now leaving the Jakafi.com website. This link will take you to a site that is not owned or maintained by Incyte Corporation, and Incyte is not responsible for the information contained on third party sites.